As biotech investors continue to wait for Arena Pharmaceuticals to launch its obesity drug Belviq, pharmaceutical company Vivus (VVUS +0.00%) has been trying to ramp up sales for its rival drug Qsymia. The company's slow drug launch has been the topic of much debate in past quarters, but it recently reported that its total number of prescriptions shipped in March were 42% greater than scripts in January. Should investors be excited about this result, or will the real catalyst for this stock be its upcoming earnings report for the first quarter of 2013? Health-care analyst Max Macaluso sheds light on this topic in the following video.
Why This Obesity Drugmaker's Prescription Data Tells Only Half the Story
By Max Macaluso – Apr 22, 2013 at 6:30PM
NASDAQ: VVUS
Vivus
Vivus released prescription data for its obesity drug Qsymia last week, but its earnings report is more important.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo